Genomic Health, Inc. (GHDX)
Q2 2012 Earnings Call
August 8, 2012 4:30 pm ET
Emily Faucette – Senior Director, Corporate Communications and Investor Relations
Kimberly Popovits – Chairman of the Board, Chief Executive Officer and President
Bradley Cole – Chief Operating Officer
Dean Schorno – Chief Financial Officer
Steven Shak – Executive Vice President of Research and Development and Chief Medical Officer
Kathy Hibbs – Senior Vice President & General Counsel
Joffre Baker – Chief Scientific Officer
Randal Scott – Founder and Director, Genomic Health and Chief Executive Officer,
Dane Leone – Macquarie Research
Tycho Peterson – JPMorgan
David Clair – Piper Jaffray
Amanda Murphy – William Blair
Dan Leonard – Leerink Swann
Kevin DeGeeter – Ladenburg Thalmann & Co.
Scott Gleason – Stephens Inc.
Laura McGuigan – B. Riley
Nicholas Jansen – Raymond James
Good afternoon. My name is Chuck, and I will be your conference operator today. At this time I would like to welcome everyone to Genomic Health’s Second Quarter 2012 Financial Results Conference Call. All participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. (Operator instructions)
I would now like to turn the call over to Emily Faucette, Senior Director of Corporate Communications and Investor Relations. You may begin your conference.
Thank you. Good afternoon everyone and welcome to Genomic Health conference call to review our second-quarter 2012 financial results. Before we begin, I would like to remind you that various remarks that we make on this call that are not historical, including those about our future financial and operating results, our plans and prospects, our ability to leverage our existing infrastructure, the success of our business strategy, economic benefits and value to payers of our tests, growth opportunities, future products, product enhancements and our product pipeline, demand for our tests and drivers of demand, payer coverage and progress in reimbursement and patient access, our investments in our business, clinical outcomes and timing of clinical studies, and product launches, and our expectations regarding our ability to comply with potential FDA regulation constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.